Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder

Brain-specific chemokine FAM19A5 induces hypothalamic inflammation

(2020) Dasol Kang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Serum FAM19A5 levels: A novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder

(2020) Kyu-Man Han et al.   BRAIN BEHAVIOR AND IMMUNITY

The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial

(2020) Mahmoud S. Abdallah et al.   Neurotherapeutics

Anti-TNF effect of combined pravastatin and cilostazol treatment in an in vivo mouse model

(2019) Hae-Ri Lee et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Celecoxib augmentation of escitalopram in treatment-resistant bipolar depression and the effects on Quinolinic Acid

(2019) Monica Feliz R. Castillo et al.   NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH

Escitalopram Ameliorates Cognitive Impairment in D-Galactose-Injected Ovariectomized Rats: Modulation of JNK, GSK-3β, and ERK Signalling Pathways

(2019) Weam W. Ibrahim et al.   Scientific Reports

Potential Anti-Inflammatory Effect of Escitalopram in Iodoacetamide-Induced Colitis in Depressed Ovariectomized Rats: Role of α7-nAChR

(2019) Salah A. Abdo et al.   INFLAMMATION

Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis

(2019) Jia Jia Liu et al.   MOLECULAR PSYCHIATRY

Anti-inflammatory properties of cilostazol: Its interruption of DNA binding activity of NF-κB from the Toll-like receptor signaling pathways

(2018) Takuya Sakamoto et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Changes in the serum levels of inflammatory cytokines in antidepressant drug-naïve patients with major depression

(2018) Wei Zou et al.   PLoS One

A review on inflammatory cytokine-induced alterations of the brain as potential neural biomarkers in post-traumatic stress disorder

(2018) Yong-Ku Kim et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

The Phosphodiesterase Inhibitor Pentoxifylline as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial

(2018) Sahar Mohamed El-Haggar et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS

Antidepressant Effects of Aripiprazole Augmentation for Cilostazol-Treated Mice Exposed to Chronic Mild Stress after Ischemic Stroke

(2017) Yu Kim et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Efficacy of escitalopram monotherapy in the treatment of major depressive disorder

(2017) Guanjun Li et al.   MEDICINE

Inflammation and depression: a causal or coincidental link to the pathophysiology?

(2017) Brian E. Leonard   ACTA NEUROPSYCHIATRICA

Cilostazol exerts antiplatelet and anti-inflammatory effects through AMPK activation and NF-kB inhibition on hypercholesterolemic rats

(2016) Nadia Alice Vieira da Motta et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor

(2016) M Fujita et al.   MOLECULAR PSYCHIATRY

Inflammation, Glutamate and Glia: A Trio of Trouble in Mood Disorders

(2016) Ebrahim Haroon et al.   NEUROPSYCHOPHARMACOLOGY

Major depressive disorder

(2016) Christian Otte et al.   Nature Reviews Disease Primers

Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial

(2015) Amirhossein Gougol et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: Implication of cilostazol for diabetes mellitus-induced dementia

(2015) Kyoung Ja Kwon et al.   NEUROBIOLOGY OF DISEASE

Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke

(2015) Yu Ri Kim et al.   PSYCHOPHARMACOLOGY

Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors

(2014) David Baumeister et al.   SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY

Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study

(2014) M Teare et al.   Trials

Rational site-directed pharmacotherapy for major depressive disorder

(2013) Pierre Blier   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression

(2013) C. N. Haile et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications

(2013) J.C. Felger et al.   NEUROSCIENCE

Alterations of Serum Levels of BDNF-Related miRNAs in Patients with Depression

(2013) You-Jie Li et al.   PLoS One

Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment

(2012) Mauro Garcia-Toro et al.   BMC Psychiatry

Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability

(2012) Eiji Kirino   Patient Preference and Adherence

cGMP Signaling, Phosphodiesterases and Major Depressive Disorder

(2011) Gillian W. Reierson et al.   Current Neuropharmacology

Effects of Repeated Treatment with Phosphodiesterase-4 Inhibitors on cAMP Signaling, Hippocampal Cell Proliferation, and Behavior in the Forced-Swim Test

(2011) L. Xiao et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Serum BDNF levels before treatment predict SSRI response in depression

(2011) Owen M. Wolkowitz et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Cilostazol, Not Aspirin, Reduces Ischemic Brain Injury via Endothelial Protection in Spontaneously Hypertensive Rats

(2011) Naoki Oyama et al.   STROKE

Time-dependent effects of escitalopram on brain derived neurotrophic factor (BDNF) and neuroplasticity related targets in the central nervous system of rats

(2010) Silvia Alboni et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Cilostazol protects mice against endotoxin shock and attenuates LPS-induced cytokine expression in RAW 264.7 macrophages via MAPK inhibition and NF-κB inactivation: Not involved in cAMP mechanisms

(2010) Won Sun Park et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Crucial role for Ser133-phosphorylated form of cyclic AMP-responsive element binding protein signaling in the differentiation and survival of neural progenitors under chronic cerebral hypoperfusion

(2009) N. Miyamoto et al.   NEUROSCIENCE

Phosphodiesterase genes and antidepressant treatment response: A review

(2008) Karin Esposito et al.   ANNALS OF MEDICINE

Novel Augmentation Therapy with Cilostazol for the Geriatric Major Depressive Disorder Patient with Deep White Matter Hyperintensities on T2-Weighted Brain MRI: A Case Report

(2008) K. Takahashi et al.   PHARMACOPSYCHIATRY